Prognostic Value of (18)F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel

BACKGROUND AND AIM: The availability of new treatments for metastatic castrate-resistant prostate cancer (mCRPC) patients increases the need for reliable biomarkers to help clinicians to choose the better sequence strategy. The aim of the present retrospective and observational work is to investigat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Contrast Media Mol Imaging
Autores principales: Quaquarini, E., D'Ambrosio, D., Sottotetti, F., Gallivanone, F., Hodolic, M., Baiardi, P., Palumbo, R., Vellani, C., Canevari, C., Bernardo, A., Castiglioni, I., Porta, C., Trifirò, G.
Formato: Artigo
Lenguaje:Inglês
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6458948/
https://ncbi.nlm.nih.gov/pubmed/31049043
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/4325946
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares